PL3724336T3 - Ulepszony związek do leczenia niewydolności serca - Google Patents

Ulepszony związek do leczenia niewydolności serca

Info

Publication number
PL3724336T3
PL3724336T3 PL18833849.5T PL18833849T PL3724336T3 PL 3724336 T3 PL3724336 T3 PL 3724336T3 PL 18833849 T PL18833849 T PL 18833849T PL 3724336 T3 PL3724336 T3 PL 3724336T3
Authority
PL
Poland
Prior art keywords
treatment
heart failure
improved compound
compound
improved
Prior art date
Application number
PL18833849.5T
Other languages
English (en)
Inventor
Thomas Thum
Sandor BATKAI
Ariana FOINQUINOS
Original Assignee
Medizinische Hochschule Hannover
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Hochschule Hannover filed Critical Medizinische Hochschule Hannover
Publication of PL3724336T3 publication Critical patent/PL3724336T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • C12N2310/113Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/32Chemical structure of the sugar
    • C12N2310/323Chemical structure of the sugar modified ring structure
    • C12N2310/3231Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/346Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/35Nature of the modification
    • C12N2310/351Conjugate
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/31Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL18833849.5T 2017-12-15 2018-12-14 Ulepszony związek do leczenia niewydolności serca PL3724336T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762599050P 2017-12-15 2017-12-15
EP17207738 2017-12-15
PCT/EP2018/085008 WO2019115788A1 (en) 2017-12-15 2018-12-14 Improved compound for treatment of heart failure

Publications (1)

Publication Number Publication Date
PL3724336T3 true PL3724336T3 (pl) 2022-08-08

Family

ID=65023844

Family Applications (1)

Application Number Title Priority Date Filing Date
PL18833849.5T PL3724336T3 (pl) 2017-12-15 2018-12-14 Ulepszony związek do leczenia niewydolności serca

Country Status (20)

Country Link
US (2) US11208651B2 (pl)
EP (1) EP3724336B1 (pl)
JP (1) JP7253834B2 (pl)
KR (1) KR102677043B1 (pl)
CN (1) CN111630168B (pl)
AU (1) AU2018383013B2 (pl)
BR (1) BR112020009532A2 (pl)
CA (1) CA3084111A1 (pl)
CL (1) CL2020001578A1 (pl)
DK (1) DK3724336T3 (pl)
ES (1) ES2910303T3 (pl)
HU (1) HUE058867T2 (pl)
IL (1) IL275273B2 (pl)
MX (1) MX2020006198A (pl)
PH (1) PH12020550589A1 (pl)
PL (1) PL3724336T3 (pl)
RS (1) RS63078B1 (pl)
SI (1) SI3724336T1 (pl)
WO (1) WO2019115788A1 (pl)
ZA (1) ZA202002529B (pl)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102019108825A1 (de) * 2019-04-04 2020-10-08 Eberhard Karls Universität Tübingen Medizinische Fakultät Verbindungen und Verfahren zur Behandlung von Erkrankungen der Leber
MX2021015552A (es) * 2019-06-14 2022-10-13 Cardior Pharmaceuticals Gmbh Tratamiento de la insuficiencia cardiaca en individuos humanos.
WO2026012462A1 (zh) * 2024-07-12 2026-01-15 上海拓界生物医药科技有限公司 靶向miR-132的反义寡核苷酸及其医药用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO5271699A1 (es) 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US7405274B2 (en) 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
EP1791954A1 (en) * 2004-09-07 2007-06-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial
US20070065840A1 (en) * 2005-03-23 2007-03-22 Irena Naguibneva Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS
ES2564823T3 (es) * 2005-05-27 2016-03-29 Ospedale San Raffaele S.R.L. Vector génico que comprende miARN
EP3211098B1 (en) * 2008-11-10 2023-03-15 Battelle Memorial Institute Method utilizing microrna to determine physiological conditions
WO2010105096A2 (en) * 2009-03-11 2010-09-16 University Of Massachusetts Modulation of human cytomegalovirus replication by micro-rna 132 (mir132), micro-rna 145 (mir145) and micro-rna 212 (mir212)
US20120107825A1 (en) * 2010-11-01 2012-05-03 Winger Edward E Methods and compositions for assessing patients with reproductive failure using immune cell-derived microrna
EP2474617A1 (en) 2011-01-11 2012-07-11 InteRNA Technologies BV Mir for treating neo-angiogenesis
EP4008786A3 (en) * 2011-09-06 2022-08-03 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. The mirna-212/132 family as a therapeutic target
CN103361428B (zh) * 2013-06-21 2016-06-22 徐州医学院 miRNA-132化合物在制备慢性疼痛诊断标志物及治疗药物中的应用
EP3230453B1 (en) * 2014-09-21 2020-05-20 Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. Downregulating mir-132 for the treatment of lipid related disorders
MX2021015552A (es) * 2019-06-14 2022-10-13 Cardior Pharmaceuticals Gmbh Tratamiento de la insuficiencia cardiaca en individuos humanos.
CN116438305A (zh) * 2020-07-23 2023-07-14 法兰克福大学 用于治疗心力衰竭的miRNA的组合抑制
CN112043721B (zh) * 2020-09-04 2022-01-28 南通大学 miR-132-5p在制备神经再生药物或材料中的应用
CN115068632A (zh) * 2022-06-22 2022-09-20 华中科技大学同济医学院附属同济医院 Ago2在制备治疗心衰的药物方面的用途及其蛋白、基因、转化体、药物与制备方法

Also Published As

Publication number Publication date
SI3724336T1 (sl) 2022-05-31
EP3724336B1 (en) 2022-02-09
CN111630168A (zh) 2020-09-04
RS63078B1 (sr) 2022-04-29
EP3724336A1 (en) 2020-10-21
PH12020550589A1 (en) 2021-04-26
CN111630168B (zh) 2023-09-22
CL2020001578A1 (es) 2020-11-06
US20220162597A1 (en) 2022-05-26
RU2020122587A (ru) 2022-01-10
AU2018383013A1 (en) 2020-06-11
KR20200104294A (ko) 2020-09-03
RU2020122587A3 (pl) 2022-01-10
MX2020006198A (es) 2020-11-24
US11208651B2 (en) 2021-12-28
IL275273B2 (en) 2024-09-01
JP2021506268A (ja) 2021-02-22
ES2910303T3 (es) 2022-05-12
IL275273A (en) 2020-07-30
KR102677043B1 (ko) 2024-06-24
IL275273B1 (en) 2024-05-01
AU2018383013B2 (en) 2024-08-22
JP7253834B2 (ja) 2023-04-07
HUE058867T2 (hu) 2022-09-28
ZA202002529B (en) 2021-08-25
BR112020009532A2 (pt) 2020-11-03
US20210180054A1 (en) 2021-06-17
US12600964B2 (en) 2026-04-14
DK3724336T3 (da) 2022-03-21
CA3084111A1 (en) 2019-06-20
WO2019115788A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
IL283837A (en) Augmented acid alpha-glucosidase for the treatment of pompe disease
IL257978B (en) Use of pasteurized akkermansia for treating metabolic disorders
EP3875139C0 (en) TREATMENT OF VENOUS DISEASES
LT3515297T (lt) Subepiderminio drėgnio verčių dvisimetriškas palyginimas
EP3632222C0 (en) BLOOD LEAD REDUCTION SUIT
IL257379A (en) Diacerein or its analogs for inhibiting expression of asc, nlrp3, and/or formation of nlrp3 inflammasome complex
IT201700081018A1 (it) Trattamento di segnali elettrofisiologici
PL3265053T3 (pl) Sposoby leczenia skóry
EP3161143C0 (en) PRODUCTION OF OLIGOSACCHARIDES
IL263680A (en) Combination therapies
PL3283527T3 (pl) Leczenie skojarzone nowotworów
PL3645002T3 (pl) Sposoby leczenia niewydolności serca za pomocą aktywatorów sarkomerów serca
PL3010910T3 (pl) Związki pirymidynodionu przeciwko chorobom serca
PL3277270T3 (pl) Kompozycje i sposoby leczenia niedokrwistości
DK3498278T3 (da) Forbindelser til behandling af sygdomme relateret til DUX4-ekspression
PT3626270T (pt) Tratamento de doenças cardiovasculares
LT3728410T (lt) Lignoceliuliozės biomasės apdorojimo būdas
EP3373918C0 (en) PRODUCTION OF CARBOXYLATED NANOCELLULOSES
IL257355B (en) Selection of patients for combination therapy
LT3307267T (lt) Išsėtinės sklerozės gydymas
PL3487491T3 (pl) Kompozycje do zwiększenia aktywności mózgu
DK3374495T3 (da) Forbedrede fremgangsmåder til vævsfremstilling
EP3016944A4 (en) COMPOUNDS FOR THE TREATMENT OF CYSTIC FIBROSIS
IL270900A (en) Treatment of cutaneous disorders
EP3595615A4 (en) GINGIVITIS TREATMENT